课题基金 / 基金详情

INTERFERON ENHANCED INTRAPERITONEAL RADIOIMMUNITY FOR OVARIAN CANCER

INTERFERON ENHANCED INTRAPERITONEAL RADIOIMMUNITY FOR OVARIAN CANCER
干扰素增强卵巢癌腹腔内放射免疫
批准号：
6303038
负责人：
ALBERT F LOBUGLIO
金额：
$2.95万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6303038
关键词：
clinical research clinical trial phase I combination cancer therapy dosage female human subject human therapy evaluation interferons monoclonal antibody neoplasm /cancer radionuclide therapy neoplasm /cancer relapse /recurrence ovary neoplasms paclitaxel peritoneal cavity radiosensitizer women's health

项目摘要

项目成果

ALBERT F LOBUGLIO的其他基金

相似基金

相关文献

中文摘要
翻译
患者接受紫杉醇和放射性标记抗体的腹腔注射。治疗总体上耐受性良好，大多数患者预期会出现可逆的骨髓抑制。紫杉醇仅对仅用放射性标记抗体注意到的骨髓抑制有最小程度的增加。
英文摘要
Patients receive intraperitoneal Taxol and radiolabeled antibody. Therapy has generally been well tolerated with expected reversible marrow suppression among most patients. Taxol has added only minimally to the marrow suppression noted with radiolabeled antibody alone.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NOVEL RADIOIMMUNOTHERAPY FOR OVARIAN CANCER
NOVEL RADIOIMMUNOTHERAPY FOR OVARIAN CANCER
Targeted immunotherapy program
NOVEL RADIOIMMUNOTHERAPY FOR OVARIAN CANCER
海外基金